Metabolic changes due to iatrogenic hypogonadism in patients with prostate cancer: orchiectomy vs. triptorelin [Metaboliske ændringer hos patienter med prostatakræft som følge af iatrogen hypogonadisme: orkiektomi vs. triptorelin]
Phase of Trial: Phase IV
Latest Information Update: 10 May 2016
Price : $35 *
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
- 04 Apr 2016 Results comparing androgen status (n = 55) presented at The 98th Annual Meeting of the Endocrine Society.
- 02 Apr 2016 Status changed from recruiting to completed, according to European Clinical Trials Database record.